IOMEPROL

First approved in 2022

Details

Stereochemistry	MIXED
Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=NJKDOADNQSYQEV-UHFFFAOYSA-N

InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)

HIDE SMILES / InChI

Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://imaging.bracco.com/us-en/bracco-s-iomeron-iomeprol-contrast-agent-optimizes-multidetector-ct-images
Curator's Comment: Description is created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/10852647

Iomeprol is a nonionic, monomeric iodinated contrast medium. Iomeprol helps optimize images obtained with sophisticated multidetector computed tomography (MDCT) technology, especially for neurological, brain, liver, cardiac and vascular scanning. The mechanism of action of Iomeprol is as a X-Ray Contrast Activity. Launched by the Bracco Group in 1995, Iomeprol (Iomeron) currently is registered in more than 40 countries worldwide, including all major European markets, Japan, and major Middle East and Asian Pacific countries.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Arteriovenous malformations 2 Sources: http://www.eisai.jp/medical/products/di/EPI/IOM_V_EPI.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For cerebral angiography Launch Date 1992
Abnormalities of the urinary system, including the kidneys, ureters, and bladder 1 Sources: http://www.eisai.com/news/enews200833pdf.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For intravenous urography Launch Date 1992
Coronary artery disease 48 Sources: http://www.eisai.jp/medical/products/di/EPI/IOM_V_EPI.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For Angiocardiography Launch Date 1992

PubMed

Title	Date	PubMed
[Multidetector CT Angiography - is it a valuable screening tool to detect significant renal artery stenosis?].	2001 Dec	11740668
Ionic and non-ionic contrast agent-mediated endothelial injury. Quantitative analysis of cell proliferation during endothelial repair.	2001 Jul	11442469
Four-dimensional cardiac imaging with multislice computed tomography.	2001 Mar 27	11274003
[Doppler evaluation of thyroid hemodynamics after intravenous administration of contrast media].	2001 Nov-Dec	11779984
Coronary angiography using 4 or 6 French diagnostic catheters: a prospective, randomized study.	2001 Oct	11581508
Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?	2003 Apr	12697241
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent.	2003 Jun	12773687
Advances in vascular and cardiac MDCT imaging: peripheral arteries.	2003 Nov	15015883
Advances in cardiac imaging.	2003 Nov	15015881
Fate of pharmaceuticals--photodegradation by simulated solar UV-light.	2003 Sep	12871743
Multislice computed tomography angiography of the abdominal arteries: comparison between computed tomography angiography and digital subtraction angiography findings in 52 cases.	2004 Jun	15230747
Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density.	2004 Oct	15304661
Analysis of iodinated X-ray contrast agents in water samples by ion chromatography and inductively-coupled plasma mass spectrometry.	2005 Aug 26	16106857
Multiphase contrast-enhanced CT of the liver with a multislice CT scanner: effects of iodine concentration and delivery rate.	2005 Feb	15786754
MDCT angiography of the pulmonary arteries: influence of iodine flow concentration on vessel attenuation and visualization.	2005 Jun	15908557
Cross-flow microfiltration with periodical back-washing for photocatalytic degradation of pharmaceutical and diagnostic residues-evaluation of the long-term stability of the photocatalytic activity of TiO2.	2005 Mar	15743630
Does iodine concentration affect the diagnostic efficacy of biphasic spiral CT in patients with hepatocellular carcinoma?	2005 May-Jun	15654576
Demonstration of cardiac involvement of sarcoidosis by contrast-enhanced multislice computed tomography and delayed-enhanced magnetic resonance imaging.	2005 Nov-Dec	16272844
Multidetector CT in abdominal aortic aneurysm treated with endovascular repair: are unenhanced and delayed phase enhanced images effective for endoleak detection?	2006 Dec	17032909
16-MDCT aortography with a low-dose contrast material protocol.	2006 Feb	16423941
Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance.	2006 Feb 14	16461822
Acute pulmonary embolism to the subsegmental level: diagnostic accuracy of three MRI techniques compared with 16-MDCT.	2006 Jul	16794142
Multislice computed tomography and magnetic resonance imaging for the assessment of reperfused acute myocardial infarction.	2006 Jul 4	16814660
Imaging of aortopulmonary collateral arteries with high-resolution multidetector CT.	2006 Jun	16555039
Improving diagnostic accuracy of MDCT coronary angiography in patients with mild heart rhythm irregularities using ECG editing.	2006 Mar	16498089
High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: iopromide 370 versus iomeprol 400.	2006 Mar	16481919
Drug eruptions to contrast media in Japan.	2006 May	16681576

Patents

Sample Use Guides

In Vivo Use Guide

IOMERON 300 Injection: each mL of IOMERON contains 612.4 mg (equivalent to 300 mg of iodine) of iomeprol. Radiological examination IOMERON 300 - 5 - 15 mL Thoracic angiography IOMERON 300 5 - 50 mL Abdominal angiography IOMERON 300 - 5 - 60 mL Peripheral anogiography IOMERON 300 - 10 - 80 mL Intravenous digital subtraction angiography IOMERON 300 - 10 - 50 mL Intraarterial digital subtraction angiography IOMERON 300 - 3 - 40 mL The dosage may be adjusted depending on the patient’s age, body weight, symptoms and purpose of use. In the case of multiple-dose administration, a total dosage of 250 mL should not be exceeded.

Route of Administration: Intravenous

In Vitro Use Guide

Iomeprol induced a time- and dose-dependent inhibition of MTT conversion in LLC-PK1-cells (75%-19% of control) at concentrations ranging from 4.7 to 75 mg I/mL after an incubation time of 2 hours and 64%-14% of control after 24 hours.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:50:10 GMT 2023` Edited by `admin` on `Fri Dec 15 17:50:10 GMT 2023`
Record UNII	17E17JBP8L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOMEPROL

Official Name

English

E-7337

Code

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE

Systematic Name

English

IOMEPROL [MI]

Common Name

English

IOMEPROL [JAN]

Common Name

English

IOMERON 300

Brand Name

English

iomeprol [INN]

Common Name

English

E7337

Code

English

Iomeprol [WHO-DD]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-

Systematic Name

English

IOMEPROL [USAN]

Common Name

English

IOMEPROL [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

V08AB10